Sorivudine is an antiviral nucleoside analog which is transported
into viral-infected cells and converted to monophosphate analogs by
virus-encoded thymidine kinases.0 cases per 1000 persons, or more
than 500,000 cases on average per year in the United States.

bacterial hemorrhagic

Janus Pharmaceuticals Inc. Announces IND Filing for JA-001

(Janus) announced the filing of an
Investigational New Drug application for a topical formulation of an
anti-viral product with previously demonstrated activity against the
varicella zoster virus (VZV) in both preclinical and clinical studies. Janus is also actively
pursuing the acquisition of additional products which will complement
their growing product portfolio.

candida diseases

fever y

It has
proven efficacy against many viruses in billion dollar markets including HIV,
hepatitis B and herpes viruses.

fungal health

viral yellow

REP 9 has been shown to be well tolerated and
to have significant efficacy in vivo in animal models of 6 different viral
infections suggesting that it will probably have significant efficacy in
humans as well.
"These presentations provide an important opportunity for REPLICor to
introduce REP 9 to the international scientific community directly involved
with antiviral research.

fevers yeast

hemorrhagic infectious

of Tokyo, Japan., a privately owned
biopharmaceutical company, is developing a broad spectrum antiviral drug
called REP 9 which has the broadest spectrum of activity in vitro ever
reported for a single chemical entity. This could result in the establishment of important
collaborations for the future development of our drug," said Andrew Vaillant,
Ph. Another example is the need to enhance our arsenal
against new strains of influenza such as the avian flu.

infections health

Janus plans to conduct clinical studies evaluating the safety and
efficacy of JA-001 (also known as ARYS-01 cream) a topical formulation
of sorivudine for the treatment of herpes zoster infections.
REPLICor will be presenting 3 papers regarding the activity of its broad
spectrum antiviral drug at the 18th International Conference on Antiviral
Research in Barcelona, Spain, April 10-14, 2005. Our broad spectrum antiviral
drug has the potential to address many of these issues," said Michel Bazinet,
MD, CEO.

REPLICor Inc.

infectious fever

aRigen has filed several patents to cover
the production method and use of the topical formulation for the
treatment of herpes zoster. LAVAL, March 30 - REPLICor Inc., chief scientific officer .

health hemorrhagic

januspharma. The 3 papers will describe the efficacy
of REP 9 when used against 1- the herpes viruses , 2- influenza and
3- hemorrhagic viruses including Ebola, Marburg and Lassa fever. An influenza pandemic
is currently considered as one of the most important threat to mankind by the
CDC and the WHO .

enterocolitica health

Janus currently has three products in development: JA-001; JA-002, a
gel formulation of a novel proprietary antibiotic targeting prevention
and treatment of bacterial infections of the skin; and JA-003, an
antibiotic cream for the treatment of acne. For more information about Janus and
its products please visit www.

candida fever

D. is a biopharmaceutical company dedicated to the discovery
and development of novel antiviral and anticancer therapeutics.

hemorrhagic viral

Sorivudine was originally discovered
by Yamasa Corporation of Chiba, Japan, and is being developed as a
topical formulation by Janus under a joint development agreement with
aRigen Inc. It has in vitro efficacy against
12 different families of viruses out of 18 families affecting humans. Each presentation will be
focused on the in vitro and in vivo results demonstrating the efficacy of
REP 9 within a specific viral family.
"There is clearly a need to develop new antiviral drugs that can address
unmet medical needs in virology. Another important problem is the development of resistant
strains of viruses to currently available drugs.

diseases candida

Over 90
percent of adults in the United States have serologic evidence of VZV
infection and are at risk for herpes zoster.com

hemorrhagic y

The annualized incidence
of herpes zoster is about 1.5 to 3.

REPLICor to disclose unique broad spectrum antiviral drug

yellow fever

Business Editors/Healthcare Editors

LOS ANGELES----

Cream Formulation of Anti-Zoster Drug to Be Evaluated in
Phase 1 Studies in the United States

Janus Pharmaceuticals Inc.
Herpes zoster, also known as shingles, results from a reactivation
of a primary varicella-zoster virus infection (chicken pox).
Janus Pharmaceuticals (Janus) is a specialty pharmaceutical
company founded in 2004 that has a growing portfolio of topical
pharmaceutical products for the treatment of infectious diseases . For example, there is no drug on the market
that can treat the Marburg virus which has killed over 100 people in Angola in
the current epidemic.